SAN FRANCISCO and SUZHOU, China, Dec. 15, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and...
Read More Details
Finally We wish PressBee provided you with enough information of ( Innovent and Lilly Expand Collaboration Through Agreement on Commercialization Rights for Jaypirca® (pirtobrutinib) in Mainland China )
Also on site :
- 'General Hospital' Fans Brace for 'Slap in the Face' amid Star's Return
- Billionaire Telegram founder leaves his $14 billion fortune to the 100+ children he’s fathered—which means $132 million for each lucky Gen Alpha kid
- Shoppers Are Racing to Walmart To Buy an 'Impressive' 834-Piece LEGO 'Star Wars' Set